Covid-19 Living Data

Study registration: *
Publication Barda N, Lancet, 2021
Dates: 2021-07-30 to 2021-09-23
Funding: Mixed (Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)
Conflict of interest: Yes (NB, ND, and RDB report institutional grants to Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. MAH reports grants from the US National Institutes of Health (NIH) and US Department of Veterans Affairs, and personal fees from Cytel and ProPublica.)

Methods
Methods	Study design:Cohort Description of participants: Individuals, 16 years or older, that received the second vaccine dose at least 5 months ago in Israel Inclusion criteria: Have received the second vaccine dose at least 5 months before the recruitment date have been eligible to receive the third vaccine dose as per the guidelines of the Israeli Ministry of Health on at least one of the days of the study period membership in the health organisation for at least 12 months no previous documented SARS-CoV-2 infection and no contact with the health-care system in the 3 days before the recruitment date. Exclusion criteria: Immunocompromised patients who received the third dose before July 30, 2021 health-care workers, live in long-term care facilities, or are medically confined to their homes (irrespective of COVID-19 individuals with missing body-mass index or residential area data. Follow-up duration (months): 1.8
Vaccines:	3 doses of BNT162b2 with at least 5 months between second and third dose.
Variant description :
Variant description :	Variant name: Delta Evidence: Indirect evidence (prevalence of variant in the population: 90 to 99%)
Documents available	Protocol Yes. In English Statistical plan Yes Data-sharing stated: No Data accessibility: NR
General comment	Main concerns are the potential for uncontrolled confounding (as the study is observational), the likelihood of informative censoring, and possible differential ascertainment of infection status.